Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.2283
- Book/Share 15.6573
- PB 1.5854
- Debt/Equity 0.6967
- CurrentRatio 1.1584
- ROIC 0.1119
- MktCap 140632079250.0
- FreeCF/Share 2.1879
- PFCF 11.3066
- PE 13.1076
- Debt/Assets 0.2998
- DivYield 0.0691
- ROE 0.1194
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Neutral
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
Read More
SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine
Published: May 21, 2025 by: PRNewsWire
Sentiment: Neutral
No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia Company plans to export PCV13 vaccine components "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently under development." SEONGNAM, South Korea , May 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it the Supreme Court of Korea has ruled in its favor in a patent infringement lawsuit filed by large global pharmaceutical giant Pfizer over its 13-valent pneumococcal …
Read More
Pfizer Thinks Bigger With 3SBio Deal
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Positive
Pfizer Inc. decided to think bigger after the Summit deal in February and that it needs control of a PD-1/VEGF bispecific antibody versus participating with its ADC pipeline. The 3SBio deal allows increased control of its oncology pipeline and much higher financial rewards in the long run, and comes at a relatively low cost. The jury is still out on the PD-1/VEGF bispecific antibody class of drugs, but the data to date make this approach worth exploring, and perhaps even necessary.
Read More
Pfizer Inks Up to $6B Deal to Market 3SBio's Cancer Drug Outside China
Published: May 20, 2025 by: Investopedia
Sentiment: Positive
Pfizer (PFE) has announced a new agreement to develop and market a cancer drug currently being developed by Chinese drugmaker 3SBio.
Read More
Buy 3 Wide Moat Stocks With Double-Digit Near-Term Upside Potential
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Three Wide Mode stocks with strong short-term upsides are: PFE, KO, DIS.
Read More
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.
Read More
Buy These 2 Beaten Down Stocks Now Before They Rally
Published: May 19, 2025 by: Seeking Alpha
Sentiment: Positive
I'm recommending two beaten-down REITs, American Assets Trust and Alexandria Real Estate, as long-term dividend plays with strong fundamentals and well-covered yields. Both stocks face near-term headwinds, but offer attractive entry points for patient investors seeking multi-year recovery and income. AAT is undervalued due to office exposure and California concentration, but has solid financials, a safe dividend, and multifamily growth potential.
Read More
PFE vs. MRK: Which Oncology Drug Giant is a Better Buy Now?
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
Both PFE and MRK have strong product and pipeline portfolios in oncology.
Read More
Astellas Presents New Data that Explores Potential of its Cancer Therapies at 2025 ASCO Annual Meeting
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
16 abstracts, including two oral presentations, feature new clinical data from Astellas' oncology portfolio TOKYO , May 19, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (May 30 - June 3). The research underscores Astellas' dedication as a pioneer in oncology and focus on clinical outcomes that matter to patients.
Read More
High-Yield Dividend Portfolios Outperform: These Are Our 5 Favorite Stock Picks
Published: May 19, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
Read More
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Published: May 18, 2025 by: The Motley Fool
Sentiment: Positive
Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal.
Read More
Pfizer's Turnaround Story Is Stronger Than You Think
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
On April 29, 2025, Pfizer beat consensus EPS estimates for the twelfth consecutive quarter by a wide margin, creating a divergence with its stock price, which continues to move sideways. I was pleasantly surprised by the strong performance of Pfizer's oncology and cardiovascular franchises, as well as the positive effects of its cost-cutting program. So, the Vyndaqel family's sales amounted to about $1.49 billion, increasing by 30.7% year-on-year, despite competition from BridgeBio's Attruby and Alnylam Pharmaceuticals' Amvuttra.
Read More
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
2 Game-Changing Additions To Your Retirement Income Portfolio
Published: May 16, 2025 by: Seeking Alpha
Sentiment: Positive
Retirement income investing should prioritize risk management, income stability, and capital preservation over aggressive growth strategies. To achieve that, investors tend to allocate high-quality value. For example, REITs, infrastructure, midstream and utilities are typical asset classes here.
Read More
New allegations about timing of Pfizer Covid vaccine passed to House panel
Published: May 15, 2025 by: WSJ
Sentiment: Negative
A former Pfizer scientist said the timing of the 2020 vaccine results “wasn't a coincidence,” according to allegations provided by a rival drugmaker.
Read More
5 Low Price-to-Book Value Stocks to Buy in May
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.
Read More
PFE vs. LLY: Which Stock Is the Better Value Option?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
4 Value Picks to Ride the Market Rebound After US-China Trade Thaw
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. STNE, CNC, CVS & PFE boast a low P/CF ratio.
Read More
Should Value Investors Buy Pfizer (PFE) Stock?
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
US-China Talks Spark Optimism; Betting Markets See Recession Odds Drop
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
A surprising thaw in US-China trade relations sparked significant optimism on Wall Street Monday. This positive development, coupled with lower recession odds, sets up a bullish long-term outlook for investors.
Read More
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
Read More
Pfizer, Eli Lilly, Other Pharma Stocks Fall as Trump Targets Lower Drug Prices
Published: May 12, 2025 by: Barrons
Sentiment: Negative
Trump said he would lower the cost of medicines for Americans by between 30% and 80%.
Read More
Pfizer (NYSE:PFE) Hasn't Been This Cheap in 13 Years. Time to Buy?
Published: May 09, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Pfizer (NYSE:PFE) is one of the world's largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.
Read More
Pfizer (PFE) Just Overtook the 20-Day Moving Average
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Positive
From a technical perspective, Pfizer (PFE) is looking like an interesting pick, as it just reached a key level of support. PFE recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Read More
5 Low Price-to-Sales Stocks That Deserve a Place in Your Portfolio
Published: May 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like PCB, GIII, ROCK, PFE and PAM hold promise.
Read More
Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Pfizer (PFE) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Dividend Harvesting Portfolio Week 218: $21,800 Allocated, $2,195.04 In Projected Dividends
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Positive
Earnings season saw strong reports from Microsoft, Apple, Meta, and Amazon, boosting the S&P 500 by 2.75% and the Nasdaq by 2.82%. The Dividend Harvesting Portfolio gained 1.98% this week, with a total return of 23.42% and forward dividend income reaching $2,195.04. Added to positions in Bristol-Myers Squibb, Pfizer, and BP, focusing on undervalued stocks with strong dividend yields and growth potential.
Read More
3 Ultra-High Yield Dividend Stocks to Buy This May
Published: May 07, 2025 by: 24/7 Wall Street
Sentiment: Positive
These three companies have a dividend yield higher than 5%. Not only are these solid business, but they have raised dividends for many years and offer capital appreciation.
Read More
Build A 12%+ Yield On Cost By 2035 With May's Top 10 High-Yield Picks
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
In this article, I present 10 attractive high-yield investment options for this month of May 2025, which not only offer dividend income but also potential for dividend growth. The selection process involves analyzing financial ratios, competitive advantages, valuations, and diversification across industries and countries to minimize risks and maximize returns. Highlighted top picks for May 2025 include VICI Properties, Chevron, Canadian Natural Resources, Pfizer, Altria, CVS Health, Toronto-Dominion Bank, Comcast, Vale, and Ares Capital.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000